Nelfinavir

also known as NFV · Nelfinavir mesylate · Viracept · NLF · A430 · AG-1343 · Nelfinavir mesilate · Nelfinavir methanesulfonate · +4 more

Other / unclassified

Developed for: HIV infectious disease · Kaposi's sarcoma · non-small cell lung carcinoma · plasma cell myeloma · cervical cancer · lung cancer · Mycobacterium avium complex disease · pancreatic adenocarcinoma
+33 more
· pancreatic neoplasm · adult liposarcoma · cancer · Castleman disease · central nervous system neoplasm · cervical carcinoma · colorectal carcinoma · cutaneous melanoma · cytomegalovirus retinitis · dysplasia of cervix · Epstein-Barr virus infection · gastric cancer · glioblastoma · glioma · head and neck squamous cell carcinoma · hepatitis C virus infection · HIV-associated nephropathy · Hodgkins lymphoma · infectious disease with sepsis · leukemia · lymphoma · myelofibrosis · nasopharyngeal carcinoma · neoplasm of mature T-cells or NK-cells · non-Hodgkin lymphoma · ovarian serous cystadenocarcinoma · plasma cell neoplasm · prostate cancer · renal cell adenocarcinoma · renal cell carcinoma · salivary gland adenoid cystic carcinoma · systemic lupus erythematosus · vulva cancer
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Cancer Institute (NCI) · Agouron Pharmaceuticals · Glaxo Wellcome · Abramson Cancer Center at Penn Medicine
+56 more
· Hoffmann-La Roche · Bristol-Myers Squibb · Mayo Clinic · Merck Sharp & Dohme LLC · Pfizer · Swiss Cancer Institute · University of Iowa · Abbott · Boehringer Ingelheim · Centers for Disease Control and Prevention · Gilead Sciences · Holden Comprehensive Cancer Center · Maastricht Radiation Oncology · Medical University of South Carolina · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of Nebraska · AIDS Associated Malignancies Clinical Trials Consortium · AIDS Malignancy Consortium · AIDS and Cancer Specimen Resource · Academic Medical Center - University of Amsterdam · Cancer Research UK · Celgene Corporation · City of Hope Medical Center · Dartmouth-Hitchcock Medical Center · Eastern Cooperative Oncology Group · Fight AIDS and Infectious Diseases Foundation · French National Agency for Research on AIDS and Viral Hepatitis · Germans Trias i Pujol Hospital · Jasper Clinic, Michigan · Kirby Institute · M.D. Anderson Cancer Center · Maastricht University Medical Center · Montefiore Medical Center · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute of Mental Health (NIMH) · National Institutes of Health (NIH) · Northwell Health · Oxford University Hospitals NHS Trust · PENTA Foundation · Pharmacia and Upjohn · St Vincent's Hospital, Sydney · Tata Memorial Hospital · The Emmes Company, LLC · The University of Texas Health Science Center, Houston · US Department of Veterans Affairs · University of Arkansas · University of California, Irvine · University of California, Los Angeles · University of California, San Diego · University of Maryland, Baltimore · University of Miami · University of Oxford · University of Washington · University of Wisconsin, Madison

Regulatory milestones approvals, filings & regulatory actions · 6 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Withdrawn	EU (EMA)	Viracept	—	2013-01-23	europa.eu ↗
Label expansions (3)	US (FDA)	VIRACEPT	—	1999-11-24 – 2004-03-19	fda.gov ↗
Approved	EU (EMA)	Viracept	—	1998-01-22	europa.eu ↗
Approved	US (FDA)	VIRACEPT	—	1997-03-14	fda.gov ↗

Trials 119 · started per year

today

US approved 1997

EU approved 1998

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02080416	Jul 2014 → Feb 2016	Castleman disease, Epstein-Barr virus infection, Hodgkins lymphoma, Kaposi's sarcoma +3	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded Stop: Enrollment
Phase 133 trials
Phase 1	NCT04169763	Aug 2020 → Dec 2026 expected	vulva cancer	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 1	NCT03829020	Apr 2019 → Sep 2022	plasma cell myeloma	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT03422874	Aug 2016 → Aug 2017	lymphoma	Dartmouth-Hitchcock Medical Center	Withdrawn	No outcome recorded
Phase 1	NCT02363829	Feb 2015 → Feb 2020	cervical carcinoma	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 1	NCT01485731	Jan 2012 → Feb 2015	cervical cancer	University of Miami	Completed	No outcome recorded
Phase 1	NCT01164709	Jul 2010 → Jul 2012	leukemia, neoplasm of mature T-cells or NK-cells, plasma cell neoplasm	Swiss Cancer Institute	Completed	No outcome recorded
Phase 1	NCT01079286	Jun 2009 → May 2011	renal cell carcinoma	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 1	NCT01086332	May 2009 → Jul 2011	pancreatic neoplasm	University of Iowa	Terminated	No outcome recorded Stop: Business
Phase 1	NCT00915694	Apr 2009 → Jul 2011	central nervous system neoplasm	Abramson Cancer Center at Penn Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01020292	Apr 2009 → Dec 2017	glioma	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 1	NCT00694837	Mar 2009 → Jan 2013	glioblastoma	Maastricht Radiation Oncology	Completed	No outcome recorded
Phase 1	NCT01068327	Nov 2007 → Aug 2013	pancreatic adenocarcinoma	University of Nebraska	Completed	No outcome recorded
Phase 1	NCT01445106	Dec 2006 → May 2011	cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00385450	Oct 2006 → Oct 2008	—	Mayo Clinic	Terminated	No outcome recorded
Phase 1	NCT00346619	Oct 2005 → Oct 2007	—	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT00307502	Jan 2005 → Dec 2009	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 1	NCT00336778	Jan 2004 → Apr 2008	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 1	NCT00346580	Jun 2003 → Sep 2005	infectious disease with sepsis	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT02257008	Mar → Dec 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00032669	Mar 2002 → Apr 2006	HIV infectious disease	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT00001766	Aug 1998 → Aug 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000893	Oct 1997 → Dec 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000902	? → Apr 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002380	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT00000887	? → Jul 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002164	—	HIV infectious disease	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00001091	? → Oct 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00004736	—	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00017758	—	HIV infectious disease, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002372	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 1	NCT00000941	? → Mar 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002381	—	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00001108	? → Jun 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/28 trials
Phase 1/2	NCT07281781	Sep 2025 → Jun 2026 overdue	myelofibrosis	University of California, Irvine	Recruiting	No outcome recorded
Phase 1/2	NCT05036226	Mar 2022 → May 2027 expected	prostate cancer	Medical University of South Carolina	Recruiting	No outcome recorded
Phase 1/2	NCT02024009	Mar 2016 → Jun 2021	pancreatic neoplasm	University of Oxford	Completed	No outcome recorded
Phase 1/2	NCT01555281	Feb 2012 → Jun 2022	plasma cell myeloma	Swiss Cancer Institute	Terminated	No outcome recorded
Phase 1/2	NCT01447589	Feb → Oct 2012	lung cancer	Oxford University Hospitals NHS Trust	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00704600	Sep 2008 → Sep 2010	colorectal carcinoma	Maastricht Radiation Oncology	Completed	No outcome recorded
Phase 1/2	NCT00589056	Jun 2007 → Mar 2012	lung cancer	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 1/2	NCT00233948	Mar 2006 → Jul 2013	adult liposarcoma	City of Hope Medical Center	Terminated	No outcome recorded
Phase 232 trials · 1 missed
Phase 2	NCT06971744	Dec 2025 → Jun 2028 expected	ovarian serous cystadenocarcinoma	Medical University of South Carolina	Recruiting	No outcome recorded
Phase 2	NCT01925378	Nov 2018 → Dec 2022	dysplasia of cervix	The University of Texas Health Science Center, Houston	Withdrawn	No outcome recorded
Phase 2	NCT03050060	Jun 2017 → Oct 2018	cutaneous melanoma, non-small cell lung carcinoma, renal cell adenocarcinoma	University of Washington	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03077451	Mar 2017 → May 2022	Kaposi's sarcoma	AIDS Malignancy Consortium	Completed	No outcome recorded
Phase 2	NCT02188537	Dec 2014 → Jul 2016	plasma cell myeloma	Swiss Cancer Institute	Completed	No outcome recorded
Phase 2	NCT02066311	Sep 2014 → Jun 2018	systemic lupus erythematosus	Northwell Health	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02207439	Jul 2014 → May 2021	head and neck squamous cell carcinoma	Abramson Cancer Center at Penn Medicine	Completed	No outcome recorded
Phase 2	NCT01728779	Jan 2014 → Mar 2020	—	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT01959672	Sep 2013 → Apr 2018	pancreatic adenocarcinoma	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT01108666	Mar 2010 → Jul 2018	non-small cell lung carcinoma	Abramson Cancer Center at Penn Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01065844	Oct 2009 → May 2015	salivary gland adenoid cystic carcinoma	University of Iowa	Completed	No outcome recorded
Phase 2	NCT00791336	Aug 2008 → Mar 2011	non-small cell lung carcinoma	University of Iowa	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00146380	Jul 2003 → Jan 2009	HIV infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 2	NCT00541463	Jan 2001 → May 2003	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00002240	Mar 1999 → Dec 2001	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT00002423	Mar 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00003008	Dec 1997 → Jun 2006	sarcoma	Eastern Cooperative Oncology Group	Completed	No outcome recorded
Phase 2	NCT00000885	? → Jun 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00000913	? → Apr 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001087	? → Jul 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000912	? → May 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002440	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00002171	—	HIV infectious disease	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00002185	—	HIV infectious disease, Kaposi's sarcoma	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00002184	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00001094	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 2	NCT00000924	? → Jun 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002235	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00002169	—	HIV infectious disease, cytomegalovirus retinitis	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00000872	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002219	—	HIV infectious disease	Gilead Sciences	Unknown	No outcome recorded
Phase 2	NCT00002170	—	HIV infectious disease, Mycobacterium avium complex disease	Agouron Pharmaceuticals	Completed	No outcome recorded

Phase 2/32 trials · 2 missed
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	Missed primary
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 313 trials · 1 missed
Phase 3	NCT03256916	Jan 2018 → May 2024	cervical cancer	Tata Memorial Hospital	Completed	No outcome recorded
Phase 3	NCT00099359	Feb 2004 → Feb 2011	HIV infectious disease	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00017719	May 2002 → Mar 2006	HIV infectious disease, pregnancy disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 3	NCT00028067	Aug 2001 → Apr 2002	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 3	NCT00009061	Nov 2000 → ?	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded
Phase 3	NCT00008554	Nov 2000 → ?	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded
Phase 3	NCT00004583	Mar 1999 → ?	HIV infectious disease	Abbott	Completed	No outcome recorded
Phase 3	NCT00028327	? → Jul 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002178	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00002397	—	HIV infectious disease, HIV-associated nephropathy	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00000903	? → Jul 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Mixed
Phase 3	NCT00002374	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT00002378	—	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded

Phase 49 trials
Phase 4	NCT00246610	Mar 2006 → Nov 2007	HIV infectious disease	Pfizer	Completed	No outcome recorded
Phase 4	NCT00312182	Mar → Jun 2006	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT00251030	Nov 2005 → Jan 2006	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT00141284	Oct 2005 → Dec 2006	HIV infectious disease, hepatitis C virus infection	Pfizer	Completed	No outcome recorded
Phase 4	NCT00192660	Feb 2003 → Oct 2006	cardiovascular disorder, lipodystrophy	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00006190	Nov 2000 → Nov 2001	HIV infectious disease, lipodystrophy	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 4	NCT00023400	Feb 2000 → Feb 2002	HIV infectious disease, tuberculosis	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 4	NCT00005000	Dec 1999 → ?	HIV infectious disease	Agouron Pharmaceuticals	Unknown	No outcome recorded
Phase 4	NCT00005106	Sep 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase not applicable21 trials · 2 missed
—	NCT00205283	Aug 2003 → Aug 2005	HIV infectious disease	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00122590	Jul 2002 → Mar 2005	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
—	NCT00016601	Jun 2001 → May 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00005762	Mar 2001 → May 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002411	Mar 1998 → Sep 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002176	May 1997 → Mar 2000	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002177	May 1997 → Mar 2000	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
—	NCT00002201	—	HIV infectious disease	Abbott	Completed	No outcome recorded
—	NCT00000892	? → Aug 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000922	? → Jan 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
—	NCT00002375	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00002216	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00006443	? → Oct 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002165	—	HIV infectious disease	Agouron Pharmaceuticals	Completed	No outcome recorded
—	NCT00000859	? → Dec 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
—	NCT00002430	—	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00000895	? → Aug 2001	HIV infectious disease, Mycobacterium avium complex disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000919	? → Nov 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000898	? → May 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000914	? → Jun 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002211	—	HIV infectious disease	Pharmacia and Upjohn	Completed	No outcome recorded

Comparator or background therapy16 trials
Phase 1	NCT00000899 Background	? → Oct 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00006211 Background	Feb 2000 → Apr 2001	HIV infectious disease	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00004985 Background	Jan 2000 → ?	HIV infectious disease	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00004998 Background	Nov 1999 → ?	HIV infectious disease	Agouron Pharmaceuticals	Suspended	No outcome recorded
Phase 2	NCT00004999 Background	Aug 1999 → ?	HIV infectious disease	Agouron Pharmaceuticals	Suspended	No outcome recorded
Phase 2	NCT00002442 Background	Jun 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00001122 Background	? → Oct 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT03631732 Comparator	Aug 2018 → Aug 2019	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT00234091 Comparator	Apr 2006 → Sep 2011	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00650637 Background	Jan → Aug 2003	diarrheal disease	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00002429 Background	Jul 1999 → Jan 2001	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00002224 Background	Mar 1999	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00005002 Background	—	HIV infectious disease	Agouron Pharmaceuticals	Unknown	No outcome recorded
Phase 4	NCT00457665 Comparator	Feb 2002 → Oct 2007	HIV infectious disease	University of Texas Southwestern Medical Center	Completed	No outcome recorded
—	NCT00006441 Background	Feb 2003 → Oct 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002215 Background	—	HIV infectious disease	Triangle Pharmaceuticals	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2004-01-20	Vertex Pharmaceuticals Incorporated	Results Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) vrtx.com ↗ In the trial, 66 percent of 166 HIV+ patients (n=109) achieved a viral load (vRNA) 400 copies/mL with LEXIVA, compared to 51 percent of 83 patients (n=42) taking nelfinavir.

All press releases naming this drug 1 release

Date	Issuer	Release
2004-01-20	Vertex Pharmaceuticals Incorporated	Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) vrtx.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 142 sources stand behind the page.

Field	Value	Cited text
Known as	nelfinavir	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 126 “It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ “receive individualized regimen of HAART for 48 weeks: nelfinavir (NEV), nevirapine (NVP), and nucleoside reverse transcriptase inhibitor(s) as per primary physician.” NCT00000895 ↗ “The HIV protease inhibitor nelfinavir (NFV) displays notable radiosensitizing effects.” PMID 30825970 ↗ Dec 2018 “nelfinavir (NFV) and efavirenz (EFV) when used in combination or separately” NCT00001087 ↗ “nelfinavir (NLV)” NCT00336778 ↗ “nelfinavir NFV)” NCT03631732 ↗ NCT00016601 ↗ NCT00002184 ↗ NCT06971744 ↗ NCT00002177 ↗ Show 116 more sources
Known as	A430	“A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With...” NCT00141284 ↗
Known as	AG-1343	ChEMBL registry synonym — accepted as the source's own label CHEMBL584 ↗
Known as	Nelfinavir mesilate	ChEMBL registry synonym — accepted as the source's own label CHEMBL584 ↗
Known as	Nelfinavir mesylate	“The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective...” NCT00006211 ↗ 20 “This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and...” NCT06971744 ↗ “Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 Mg q24h” NCT00002235 ↗ “VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.” NCT02024009 ↗ “To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients” NCT00002165 ↗ “Nelfinavir mesylate (Viracept) is an inhibitor of the HIV protease 1.” NCT01555281 ↗ “Viracept (Nelfinavir Mesylate)” NCT00004999 ↗ “Drug: Nelfinavir Mesylate” NCT03077451 ↗ “nelfinavir mesylate (NFV)” NCT00039741 ↗ “Nelfinavir mesylate” NCT00002201 ↗ “Nelfinavir mesylate” NCT00000887 ↗ Show 10 more sources
Known as	Nelfinavir methanesulfonate	ChEMBL registry synonym — accepted as the source's own label CHEMBL584 ↗
Known as	Nelfinaviri mesilas	ChEMBL registry synonym — accepted as the source's own label CHEMBL584 ↗
Known as	NEV	“receive individualized regimen of HAART for 48 weeks: nelfinavir (NEV), nevirapine (NVP), and nucleoside reverse transcriptase inhibitor(s) as per primary physician.” NCT00000895 ↗
Known as	NFV	“The purpose of this study is to assess the impact of prospective drug level monitoring and dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group...” NCT00205283 ↗ 35 “Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and...” NCT02363829 ↗ “This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and...” NCT06971744 ↗ “This is a phase 2 trial of the HIV protease inhibitor (HPI) Nelfinavir (NFV) in combination with radiotherapy and chemotherapy in patients with locally advanced non-small cell...” NCT00791336 ↗ “In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine,...” PMID 11372025 ↗ May 2001 “Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV),...” PMID 16048950 ↗ Aug 2005 “Each regimen consists of 4 drugs that include a combination of nucleoside reverse transcriptase inhibitors (stavudine, lamivudine, zidovudine, didanosine, zalcitabine) plus...” NCT00000902 ↗ “either nelfinavir (NFV) 30 mg/kg twice daily (bid), ritonavir (RTV) 400 mg/m bid and buffered didanosine (ddI) 240 mg/m daily (arm A) or NFV 50-55 mg/kg bid, nevirapine (NVP)...” PMID 16220085 ↗ Oct 2005 “Nelfinavir (NFV), an FDA-approved protease inhibitor for the treatment of HIV, has been shown to be a potent activator of lytic gene expression of EBV(+) and KSHV(+) cancer cell lines.” NCT02080416 ↗ “Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV).” NCT00000919 ↗ “The 7 drugs that will be given in this study are stavudine (d4T), didanosine (ddI), lamivudine (3TC), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and nevirapine (NVP).” NCT00001108 ↗ Show 25 more sources
Known as	NLF	“The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).” NCT00002211 ↗ 1 “Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).” NCT00002224 ↗
Known as	NLV	“nelfinavir (NLV)” NCT00336778 ↗
Known as	NSC-747167	ChEMBL registry synonym — accepted as the source's own label CHEMBL584 ↗
Known as	Viracept	“A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With...” NCT00141284 ↗ 10 “The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective...” NCT00006211 ↗ “An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1...” NCT00002381 ↗ “A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant...” NCT00000887 ↗ “Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 Mg q24h” NCT00002235 ↗ “These patients are eligible to receive funding for up to a 3-month supply of nelfinavir (Viracept) and Combivir.” NCT00005002 ↗ “To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients” NCT00002165 ↗ “Viracept (Nelfinavir Mesylate)” NCT00004999 ↗ “Nelfinavir (Viracept®) 1250 mg” NCT02207439 ↗ “nelfinavir (Viracept)” NCT00002215 ↗ “Viracept (nelfinavir)” NCT00004998 ↗
Action	Inhibit	“other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir)” NCT00000892 ↗
Modality	Other / unclassified	“Protease Inhibitor” NCT00000919 ↗
Route	Oral	“Oral Nelfinavir” NCT00000887 ↗